To become one of top 20 global players for innovative products, including the small volume of parenteral and lyophilized injections and eye-care products.
Proton pump inhibitors
Antimalarial
Anti-inflammatory
Anesthetics including protocol
Ophthalmic
Anti-infective
Antifungal
Ciron to have 2 of the top 10 brands in derma segment.
To invest in R&D and develop new products as per our mission.
To start the API division by March 2018.
File at least 20 ANDA's / Dossiers in USA, EU, Australia, and other regulated markets.